FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367721023> ?p ?o ?g. }

• W4367721023 abstract "<h3>Background and Importance</h3> Interstitial lung diseases (ILD) is a group of rare diseases with bad prognosis, being Idiopathic pulmonary fibrosis (IPF) the most frequent of them. They can be treated with antifibrotic drugs: nintedanib or pirfenidone. However, these drugs have a high rate of adverse effects, which has a significant impact on treatment persistence. <h3>Aim and Objectives</h3> To analyse the safety of pirfenidone and nintedanib in patients with ILD as well as treatment’s persistence, in a third-level hospital. <h3>Material and Methods</h3> Retrospective observational study of patients with ILD treated with antifibrotic drugs from January 2016 to August 2022. Variables: sex, age, drug, duration of antifibrotic treatment, associated drug, switch to another antifibrotic drug, side effects, discontinuations, deaths. Information was collected from the hospital’s information systems. <h3>Results</h3> 66 patients, 67% men, mean age 67 (47–86). 44 patients with nintedanib: 23 IPF, 14 progressive pulmonary fibrosis (PPF), 2 ILD associated with systemic sclerosis, 4 fibroemphysema and 1 ILD not classified. 5 of them were treated with an associated immunosuppressive drug: mycophenolate mofetil. 12 patients needed a dose reduction due to gastrointestinal effects: 100% diarrhea, 80% nausea. 1 patient needed temporary discontinuation due to increased transaminases, which were finally stabilised, being able to return to a higher dose. 2 patients needed discontinuation of treatment due to bleeding: 1 patient was on antiplatelet therapy and the other had a background of epistaxis. These two patients switched to pirfenidone. 22 patients with pirfenidone: all of them IPF. 2 patients needed dose reduction due to diarrhoea and 2 needed treatment discontinuation due to severe sunburns. These patients switched to nintedanib. <h3>Persistence until progression</h3> 18 months with nintedanib and 24 months with pirfenidone. 8 patients died during treatment, 4 of them because of COVID-19 infection. <h3>Conclusion and Relevance</h3> Thanks to a close follow-up in patients with ILD, it is possible to modify the dose and to achieve greater tolerance to treatments. The pandemic affected negatively during the year 2020, not only because of the impossibility of receiving medical appointments, but also due to the acceleration of their death. The rapid establishment of anti-fibrotic treatment and the adequate control of adverse effects are the key for this type of patients. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest" @default.
• W4367721023 created "2023-05-04" @default.
• W4367721023 creator A5012613732 @default.
• W4367721023 creator A5017833801 @default.
• W4367721023 creator A5029135402 @default.
• W4367721023 creator A5033055030 @default.
• W4367721023 creator A5039838330 @default.
• W4367721023 date "2023-03-01" @default.
• W4367721023 modified "2023-10-17" @default.
• W4367721023 title "5PSQ-098 Safety and persistence of anti-fibrotic drugs in interstitial lung diseases" @default.
• W4367721023 doi "https://doi.org/10.1136/ejhpharm-2023-eahp.451" @default.
• W4367721023 hasPublicationYear "2023" @default.
• W4367721023 type Work @default.
• W4367721023 citedByCount "0" @default.
• W4367721023 crossrefType "proceedings-article" @default.
• W4367721023 hasAuthorship W4367721023A5012613732 @default.
• W4367721023 hasAuthorship W4367721023A5017833801 @default.
• W4367721023 hasAuthorship W4367721023A5029135402 @default.
• W4367721023 hasAuthorship W4367721023A5033055030 @default.
• W4367721023 hasAuthorship W4367721023A5039838330 @default.
• W4367721023 hasBestOaLocation W43677210231 @default.
• W4367721023 hasConcept C126322002 @default.
• W4367721023 hasConcept C197934379 @default.
• W4367721023 hasConcept C2777543607 @default.
• W4367721023 hasConcept C2777714996 @default.
• W4367721023 hasConcept C2778341716 @default.
• W4367721023 hasConcept C2778715236 @default.
• W4367721023 hasConcept C2779832356 @default.
• W4367721023 hasConcept C2780171596 @default.
• W4367721023 hasConcept C2780580376 @default.
• W4367721023 hasConcept C71924100 @default.
• W4367721023 hasConcept C90924648 @default.
• W4367721023 hasConceptScore W4367721023C126322002 @default.
• W4367721023 hasConceptScore W4367721023C197934379 @default.
• W4367721023 hasConceptScore W4367721023C2777543607 @default.
• W4367721023 hasConceptScore W4367721023C2777714996 @default.
• W4367721023 hasConceptScore W4367721023C2778341716 @default.
• W4367721023 hasConceptScore W4367721023C2778715236 @default.
• W4367721023 hasConceptScore W4367721023C2779832356 @default.
• W4367721023 hasConceptScore W4367721023C2780171596 @default.
• W4367721023 hasConceptScore W4367721023C2780580376 @default.
• W4367721023 hasConceptScore W4367721023C71924100 @default.
• W4367721023 hasConceptScore W4367721023C90924648 @default.
• W4367721023 hasLocation W43677210231 @default.
• W4367721023 hasOpenAccess W4367721023 @default.
• W4367721023 hasPrimaryLocation W43677210231 @default.
• W4367721023 hasRelatedWork W2979280297 @default.
• W4367721023 hasRelatedWork W3047341706 @default.
• W4367721023 hasRelatedWork W3213409369 @default.
• W4367721023 hasRelatedWork W3215535255 @default.
• W4367721023 hasRelatedWork W4205609963 @default.
• W4367721023 hasRelatedWork W4247250061 @default.
• W4367721023 hasRelatedWork W4296709027 @default.
• W4367721023 hasRelatedWork W4311236132 @default.
• W4367721023 hasRelatedWork W4327683141 @default.
• W4367721023 hasRelatedWork W4367052859 @default.
• W4367721023 isParatext "false" @default.
• W4367721023 isRetracted "false" @default.
• W4367721023 workType "article" @default.